Abstract
Context: Several randomized clinical trials (RCTs) have recently tested adjuvant chemotherapy to high-risk prostate cancer patients (PCA) after primary local therapy. Objective: The aim of the study was to perform a systematic review and meta-analysis of RCTs evaluating the adjuvant chemotherapy in high-risk prostate cancer patients after primary local therapy. The primary endpoint was overall survival (OS). The secondary endpoint was disease-free survival (DFS) and biochemical recurrence-free survival (BRFS). Methods: A systematic review of PubMed/Medline, Embase, and Cochrane databases was performed to identify relevant studies published in English up to March 2020. Six trials were selected for inclusion. Results: There were 7 studies included in the present study. The meta-analysis did not show a significant OS benefit from adjuvant chemotherapy in patients with high-risk prostate cancer after primary local therapy (hazard ratio [HR]: 0.87; 95% confidence interval [CI], 0.72–1.05; p = 0.15). But docetaxel in patients with high-risk prostate cancer after primary local therapy was associated with a slightly OS improvement (HR: 0.79; 95% CI, 0.63–0.98; p = 0.03). It also did not show a significant benefit in DFS and BRFS in patients with high-risk prostate cancer (HR: 0.89, 95% CI, 0.75–1.06, p = 0.18; HR: 0.85, 95% CI, 0.69–1.06, p = 0.16). Conclusions: This meta-analysis shows a slightly OS benefit from docetaxel in patients with high-risk prostate cancer after primary local therapy. It did not show a significant benefit in DFS and BRFS from adjuvant chemotherapy in patients with high-risk prostate cancer.
References
1.
Siegel
RL
, Miller
KD
, Jemal
A
. Cancer statistics, 2016
. CA Cancer J Clin
. 2018
;66
(1
):7
–30
. .2.
Pound
CR
, Partin
AW
, Eisenberger
MA
, Chan
DW
, Pearson
JD
, Walsh
PC
. Natural history of progression after PSA elevation following radical prostatectomy
. JAMA
. 1999
;281
(17
):1591
–7
. .3.
Ward
JF
, Blute
ML
, Slezak
J
, Bergstralh
EJ
, Zincke
H
. The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy
. J Urol
. 2003
;170
(5
):1872
–6
. .4.
Moul
JW
, Wu
H
, Sun
L
, McLeod
DG
, Amling
C
, Donahue
T
, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy
. J Urol
. 2004
;171
(3
):1141
–7
. .5.
Scher
HI
, Eisenberger
M
, D’Amico
AV
, Halabi
S
, Small
EJ
, Morris
M
, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the prostate-specific antigenworking group(J)
. J Clin Oncol
. 2004
;22
(3
):537
–56
.6.
Huggins
C
, Stevens
RE
, Hodges
CV
. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland(J)
. Arch Surg
. 1941
;43
(2
):209
–23
.7.
Böhmer
D
, Wirth
M
, Miller
K
, Budach
V
, Heidenreich
A
, Wiegel
T
. Radiotherapy and hormone treatment in prostate cancer: the use of combined external beam radiotherapy and hormonal therapy in the management of localized and locally advanced prostate cancer(J)
. Dtsch Arztebl Int
. 2016
;113
(14
):235
.8.
Sweeney
CJ
, Chen
Y-H
, Carducci
M
, Liu
G
, Jarrard
DF
, Eisenberger
M
, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer
. N Engl J Med
. 2015
;373
(8
):737
–46
. .9.
Petrylak
DP
, Tangen
CM
, Hussain
MH
, Lara
PN
, Jones
JA
, Taplin
ME
, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
. N Engl J Med
. 2004
;351
(15
):1513
–20
. .10.
James
ND
, Sydes
MR
, Clarke
NW
, Mason
MD
, Dearnaley
DP
, Spears
MR
, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial(J)
. Lancet
. 2016
;387
(10024
):1163
–77
.11.
Hussain
M
, Tangen
CM
, Thompson
IM
Jr, Swanson
GP
, Wood
DP
, Sakr
W
, et al. Phase III intergroup trial of adjuvant androgen deprivation with or without mitoxantrone plus prednisone in patients with high-risk prostate cancer after radical prostatectomy: SWOG S9921(J)
. J Clin Oncol
. 2018
;36
(15
):1498
.12.
Oudard
S
, Latorzeff
I
, Caty
A
, Miglianico
L
, Sevin
E
, Hardy-Bessard
AC
, et al. Effect of adding docetaxel to androgen-deprivation therapy in patients with high-risk prostate cancer with rising prostate-specific antigen levels after primary local therapy: a randomized clinical trial(J)
. JAMA Oncol
. 2019
;5
(5
):623
–32
.13.
Moher
D
, Liberati
A
, Tetzlaff
J
, Altman
DG
. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
. BMJ
. 2009
;339
:b2535
.14.
Higgins
JP
, Thompson
SG
, Deeks
JJ
, Altman
DG
. Measuring inconsistency in meta-analyses
. BMJ
. 2003
;327
(7414
):557
–60
. .15.
Rosenthal
SA
, Hu
C
, Sartor
O
, et al. Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial
. J Clin Oncol
. 2019
;37
(14
):1159
–1168
.16.
Carles
J
, Gallardo
E
, Doménech
, et al. Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients
. Int J Radiat Oncol Biol Phys
. 2019
;103
(2
):344
–352
.17.
Messing
EM
, Manola
J
, Sarosdy
M
, Wilding
G
, Crawford
ED
, Trump
D
. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer
. N Engl J Med
. 1999
;341
(24
):1781
–8
. .18.
James
ND
, de Bono
JS
, Spears
MR
, Clarke
NW
, Mason
MD
, Dearnaley
DP
, et al. Abiraterone for prostate cancer not previously treated with hormone therapy(J)
. N Engl J Med.
2017
;377
(4
):338
.19.
Klotz
LH
, Goldenberg
SL
, Jewett
MA
, Fradet
Y
, Nam
R
, Barkin
J
, et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy
. J Urol
. 2003
;170
(3
):791
–4
. .20.
Lin
DW
, Shih
MC
, Aronson
W
, Basler
J
, Beer
TM
, Brophy
M
, et al. Veterans affairs cooperative studies program study# 553: chemotherapy after prostatectomy for high-risk prostate carcinoma: a phase iii randomized study(J)
. Eur Urol
. 2020 May
;77
(5
):563
–72
.21.
Ahlgren
GM
, Flodgren
P
, Tammela
TLJ
, Kellokumpu-Lehtinen
P
, Borre
M
, Angelsen
A
, et al. Docetaxel versus surveillance after radical prostatectomy for high-risk prostate cancer: results from the prospective randomised, open-label phase 3 scandinavian prostate cancer group 12 trial(J)
. Eur Urol
. 2018
;73
(6
):870
–6
.22.
Febbo
PG
, Richie
JP
, George
DJ
, Loda
M
, Manola
J
, Shankar
S
, et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer
. Clin Cancer Res
. 2005
;11
(14
):5233
–40
. .23.
Bergstrom
CP
, Ruffell
B
, Ho
CMT
, Higano
CS
, Ellis
WJ
, Garzotto
M
, et al. Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates[J]
. Anti Cancer Drugs
. 2016
;28
(1
):1
.24.
Bandini
M
, Fossati
N
, Gandaglia
G
, Preisser
F
, Dell’Oglio
P
, Zaffuto
E
, et al. Neoadjuvant and adjuvant treatment in high-risk prostate cancer[J]
. Expert Rev Clin Pharmacol
. 2018
;11
(4
):425
–38
.25.
Tannock
IF
, De Wit
R
, Berry
WR
, Horti
J
, Pluzanska
A
, Chi
KN
, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
. N Engl J Med
. 2004
;351
(15
):1502
–12
. .26.
Ogura
T
, Tanaka
Y
, Tamaki
H
, Harada
M
. Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells
. Int J Oncol
. 2016
;48
(6
):2330
–8
. .27.
Zhu
Y
, Liu
C
, Armstrong
C
, Lou
W
, Sandher
A
, Gao
AC
. Antiandrogens inhibit ABCB1 efflux and atpase activity and reverse docetaxel resistance in advanced prostate cancer
. Clin Cancer Res
. 2015
;21
(18
):4133
. .28.
Komura
K
, Jeong
SH
, Hinohara
K
, Qu
F
, Wang
X
, Hiraki
M
, et al. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression
. Proc Natl Acad Sci USA
. 2016
;113
(22
):6259
–64
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
